Výsledky vyhledávání - "Kristy Drafahl"

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Autor: David Smith, Kevin Hawkins, Kristy Drafahl, Cindy Spittle, Chad Galderisi, Cristen Graham, Shouryadeep Srivastava, Scott Verrow, Victor M. Rivera, Christine Glynn

Publikováno v: Blood. 132:1558-1558

In Ph+ ALL, the absence of detectable disease has shown prognostic value for a reduced risk of relapse and improved survival. However, as the level of undetectable disease is determined by the lower limit of detection of the test in use, standardizat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1163f687380895339af1ca76832b6da
https://doi.org/10.1182/blood-2018-99-113172

Zobrazit plný text záznamu

Development and Validation Of Highly Sensitive Mrdx BCR-ABL Test For Monitoring Deep Molecular Response In Patients With Chronic Myeloid Leukemia

Autor: Jonathan Eibl, Kristy Drafahl, Chad Galderisi, Julie Toplin, Clark Fjeld, Staci McAdams, Thomas Yager, Kevin Hawkins

Publikováno v: Blood. 122:2617-2617

Treatment of chronic myeloid leukemia (CML) patients with tyrosine kinase inhibitors (TKI) has led to progressively lower levels of disease burden and higher rates of complete molecular responses. Very few assays with an analytical sensitivity of 4.5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67103e1f471e7d3a97187a53e8421d5b
https://doi.org/10.1182/blood.v122.21.2617.2617

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání